<DOC>
	<DOC>NCT02805738</DOC>
	<brief_summary>A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet</brief_summary>
	<brief_title>Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 Tablet</brief_title>
	<detailed_description>A Multicenter, Randomized, Double-blind, Parallel Design, Phase III Clinical Trial to Evaluate the Efficacy and Safety of CKD-390 tablet and Viread® tablet in Chronic hepatitis B Patients Subjects will receive either a single oral dose of the test formulation(CKD-390) or a oral dose of the reference formulation(viread).</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>1. male or female older than 19 years at the time of screening 2. Patients who have chronic hepatitis B disease are taken Viried for 6 months 3. Patients who show HBV DNA undetected(less than 20 IU/mL) 4. Patients who show positive HBsAg 5. Patients who show positive HBeAg or negative HBeAg 6. Patients who fully understand the clinical trials after indepth explanation, decided to join the clinical trials by their will and signed inform consent 1. Patients who are not taken any antiviral agents except Viread Tab 2. Patients who have hepatitis C (HCV), hepatitis D (HDV), or human immunodeficiency virus (HIV) 3. Patients who have seroperitoneum, icterus, hepatic encephalopathy, variceal hemorrhage or Patients with following value at screening total bilirubin &gt; Upper normal limit x 1.5 prothrombin time(INR) &gt; Upper normal limit x 1.5 platelets &lt; 75,000/ul serum albumin &lt; 3.0g/dl 4. Patients who are estimated to have hepatocellular carcinoma (HCC) through imaging examination or showed alphafetoprotein(AFP) more than 50ng/mL 5. Patients who show Creatinine Clearance &lt; 50 mL/min by calculating CockcroftGault equation 6. Patients with disease like heart failure, renal failure, pancreatitis that investigators consider ineligible for this study 7. Patients who have other hepatic diseases like hematochromatosis, Wilson's disease, alcoholic cirrhosis, autoimmune hepatic diseases, α1 antitrypsin deficit syndrome 8. Patients with genetic disease like Galactose intolerance, lapplactase deficiency, Glucosegalactose malabsorption 9. History of malignant tumor within 5 years 10. Patients who take any other investigational product within 30 days 11. Patients who have to administer immunosuppressants or Nephrotoxic drugs, Hepatotoxic drugs for period of Clinical Trial 12. Pregnant, breastfeeding and childbearing age who don't use adequate contraception 13. Patients who receive an organ transplant or bone marrow transplant or are going to received surgury 14. History of allergic reaction to the investigational product 15. Patients that investigators consider ineligible for this study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Chronic Hepatitis B</keyword>
	<keyword>tenofovir</keyword>
	<keyword>CKD-390</keyword>
</DOC>